Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

In a regulatory filing, the company states: “On April 10, 2025, the Board of Directors of Accelerate Diagnostics (AXDX), Inc., a Delaware corporation, unanimously elected Paul Shalhoub and ...

Bluejay Diagnostics (BJDX) announced acceptance of an abstract related to the Symphony IL-6 Test, the company’s lead product candidate, for ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% of ...

A recent study published in Neurology reveals significant diagnostic instability in Parkinson's disease, with 13.3% of diagnoses revised over a 10-year follow-up period. When dementia with ...

Tecan Group today announced an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics ...

Get Instant Summarized Text (Gist) A novel diagnostic technique using peptide nucleic acid (PNA) probes achieves near 100% accuracy in identifying pathogens within three hours. This method, based ...

CEO of Caristo Diagnostics. "With CPT approval, we are laying the foundation for a future where every at-risk American has access to precision risk assessment, moving heart care from late-stage ...

Right now, current human-led diagnostic methods are around 78.91% to 80.93% accurate. Endometrial cancer is treatable and, if found in time, has a good five-year outcome for patients. However ...